



Standard Guide for Characterization and Testing of Hyaluronan as Starting Materials Intended for Use in Biomedical and Tissue Engineered Medical Product Applications¹

This standard is issued under the fixed designation F 2347; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

INTRODUCTION

Hyaluronan, which in this guide will encompass hyaluronic acid, hyaluronate, and its salt forms, is the simplest of the glycosaminoglycans. Hyaluronan is soluble in water and forms highly viscous solutions. Hyaluronan is found in ubiquitously in the body as part of the extracellular matrix of tissues, with high concentrations in the synovial fluid, vitreous humor, and skin, as well as in cartilage. Hyaluronan has found uses in a variety of products ranging from viscosupplements (treatment of osteoarthritis), adhesion prevention (prevention of post-surgical adhesions), viscoelastics (ocular protection), and dermal implants (lip augmentation and wrinkle removal). New applications, such as scaffolds for tissue engineering, are emerging. The aim of this guide is to identify key parameters relevant to the characterization of hyaluronan for the development of new commercial applications of hyaluronan for the biomedical and pharmaceutical industries.

1. Scope

1.1 This guide covers the evaluation of hyaluronan suitable for use in biomedical or pharmaceutical applications, or both, including, but not limited to, Tissue Engineered Medical Products (TEMPs).

1.2 This guide addresses key parameters relevant to the characterization and purity of hyaluronan.

1.3 As with any material, some characteristics of hyaluronan may be altered by processing techniques, such as cross-linking and sterilization, required for the production of a specific formulation or device. Therefore, properties of fabricated forms of this polymer should be evaluated using test methods that are appropriate to ensure safety and efficacy and are not addressed in this guide.

1.4 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory requirements prior to use.*

2. Referenced Documents

2.1 ASTM Standards:²

D 2196 Test Methods for Rheological Properties of Non-Newtonian Materials by Rotational (Brookfield) Viscometer

F 619 Practice for Extraction of Medical Plastics

F 748 Practice for Selecting Generic Biological Test Methods for Materials and Devices

F 749 Practice for Evaluating Material Extracts by Intracutaneous Injection in the Rabbit

F 756 Practice for Assessment of Hemolytic Properties of Materials

F 763 Practice for Short-Term Screening of Implant Materials

F 813 Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices

F 895 Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity

¹ This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.42 on Biomaterials and Biomolecules for TEMP.

Current edition approved Nov. 1, 2003. Published December 2003.

² For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

- F 981 Practice for Assessment of Compatibility of Biomaterials (Nonporous) for Surgical Implants with Respect to Effect of Materials on Muscle and Bone
- F 1251 Terminology Relating to Polymeric Biomaterials in Medical and Surgical Devices
- F 1439 Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials
- F 1903 Practice for Testing for Biological Responses to Particles *in vitro*
- F 1904 Practice for Testing the Biological Responses to Particles *in vivo*
- F 1905 Practice for Selecting Tests for Determining The Propensity of Materials to Cause Immunotoxicity
- F 1906 Practice for Evaluation of Immune Responses in Biocompatibility Testing Using ELISA Tests, Lymphocyte Proliferation, and Cell Migration
- 2.2 *USP Documents*:³
- USP <61> Microbial Limit Tests
- USP <71> Sterility Tests
- USP <85> Bacterial Endotoxins Tests
- USP <231> Heavy Metals
- USP <731> Loss on Drying
- USP <1211> Sterilization and Sterility Assurance of Compendial Articles
- 2.3 *EP Documents*:⁴
- EP Monograph 1472 Sodium Hyaluronate
- EP 2.6.1 Sterility
- 2.4 *Other Referenced Documents*:
- ISO 10993 Biological Evaluation of Medical Devices⁵
- ISO 10993-1 Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing
- ISO 10993-7 Biological Evaluation of Medical Devices—Part 7: Ethylene Oxide Sterilization Residuals
- ISO 10993-9 Biological Evaluation of Medical Devices—Part 9: Framework for Identification and Quantification of Potential Degradation Products
- ISO 10993-17 Biological Evaluation of Medical Devices—Part 17: Establishment of Allowable Limits for Leachable Substances
- ISO 14160-1998 Sterilization of Single-Use Medical Devices Incorporating Materials of Animal Origin—Validation and Routine Control of Sterilization by Liquid Chemical Sterilants⁵
- ISO 11737-1: 1995 Sterilization of Medical Devices—Microbiological Methods—Part 1: Estimation of Population of Microorganisms on Products⁵
- ISO 11737-2: 1998 Sterilization of Medical Devices—Microbiological Methods—Part 2: Tests of Sterility Performed in the Validation of a Sterilization Process⁵
- ISO 13408-1: 1998 Aseptic Processing of Health Care Products—Part 1: General Requirements⁵
- ISO EN 12442-1 Animal Tissues and Their Derivative

- Utilized in the Manufacture of Medical Devices—Part 1: Analysis and Management of Risk⁵
- ISO EN 12442-3 Animal Tissues and Their Derivative Utilized in the Manufacture of Medical Devices—Part 3: Validation of the Elimination and/or inactivation of Virus and Transmissible Agents⁵
- International Conference on Harmonization (ICH) S2B Genotoxicity A Standard Battery for Genotoxicity Testing of Pharmaceuticals (July 1997)⁶
- International Conference on Harmonization (ICH) Q1A ICH Harmonized Tripartite Guidance for Stability Testing of New Drug Substances and Products (September 2001, Revision 1)⁶
- FDA Guideline on Validation of the Limulus Amebocyte Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products and Healthcare Products, DHHS, December 1987⁷
- FDA Interim Guidance for Human and Veterinary Drug Products and Biologicals, Kinetic LAL Techniques, DHHS, July 15, 1991⁷
- AAMI TIR No. 7: 1999 Chemical Sterilants and High Level Disinfectants: A Guide to Selection and Use⁸
- AAMI ST67/CDV-2: 1999 Sterilization of Medical Devices—Requirements for Products Labeled “Sterile”⁸
- 21 CFR 312 FDA Title 21, Food and Drugs, Investigational New Drug Applications⁹

3. Terminology

3.1 Definitions:

3.1.1 *hyaluronan*, *n*—a polysaccharide with a disaccharide repeating unit composed of D-glucuronic acid and N-acetyl-D-glucosamine in β -(1 \rightarrow 3) linkage. Each disaccharide unit is attached to the next by β -(1 \rightarrow 4) bonds. Hyaluronan is a linear polymer. Other common names are hyaluronic acid and sodium hyaluronate.

3.1.2 *hydrocolloid*, *n*—a water-soluble polymer of colloidal nature when hydrated.

3.1.3 *molecular mass average (molecular weight average)*, *n*—the given molecular weight (*M_w*) of hyaluronan will always represent an average of all of the molecules in the population. The most common ways to express the *M_w* are as the number average (\bar{M}_n) and the weight average (\bar{M}_w). The two averages are defined by the following equations:

$$\bar{M}_n = \frac{\sum_i N_i M_i}{\sum_i N_i} \quad \text{and} \quad \bar{M}_w = \frac{\sum_i w_i M_i}{\sum_i w_i} = \frac{\sum_i N_i M_i^2}{\sum_i N_i M_i}$$

where:

N_i = number of molecules having a specific molecular weight *M_i*, and

³ Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852.

⁴ Available from European Directorate for the Quality of Medicines (EDQM), Council of Europe, BP 907, 67029 Strasbourg, France.

⁵ Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036.

⁶ Available from ICH Secretariat, c/o IFPMA, 30 rue de St-Jean, P.O. Box 758, 1211 Geneva 13, Switzerland.

⁷ Available from U.S. Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857-0001.

⁸ Available from Association for the Advancement of Medical Instrumentation, 1110 North Glebe Rd., Suite 220, Arlington, VA 22201-4795.

⁹ Available from Standardization Documents Order Desk, DODSSP, Bldg. 4, Section D, 700 Robbins Ave., Philadelphia, PA 19111-5098

w_i = weight of molecules having a specific molecular weight M_i .

In a polydisperse molecular population the relation $\overline{M}_w > \overline{M}_n$ is always valid. The coefficient $\overline{M}_w / \overline{M}_n$ is referred to as the polydispersity index, and will typically be in the range 1.2 to 3.0 for commercial hyaluronan.

3.1.4 *depolymerization, n*—reduction in length of a polymer chain to form shorter polymeric units. Depolymerization may reduce the polymer chain to smaller molecular weight polymers, oligomeric, or monomeric units, or combination thereof. In hyaluronan, acid hydrolysis of the glycosidic bonds is the primary mechanism.

3.1.5 *degradation, n*—change in the chemical structure, physical properties or appearance of a material. Degradation of polysaccharides occurs via cleavage of the glycosidic bonds, usually by acid catalyzed hydrolysis. Degradation can also occur thermally and by alkali. It is important to note that degradation is not synonymous with decomposition. Degradation is often used as a synonym for depolymerization when referring to polymers. Degradation (depolymerization) of hyaluronan may also occur enzymatically by the action of hyaluronidases.

3.1.6 *decomposition, n*—structural changes of hyaluronan due to exposure to environmental, chemical, or thermal factors. Decomposition may occur at temperatures as low as 121°C during autoclaving. Decomposition can result in deleterious changes to the hyaluronan.

3.1.7 *pyrogen, n*—any substance that produces fever when administered parenterally.

3.1.8 *endotoxin, n*—a high molecular weight lipopolysaccharide (LPS) complex associated with the cell wall of gram-negative bacteria that is pyrogenic in humans. Though endotoxins are pyrogens, not all pyrogens are endotoxins.

3.1.9 *non-animal derived, n*—a term describing the absence of any animal-derived tissue, proteins, or products in the manufacturing process.

4. Significance and Use

4.1 This guide contains a listing of those characterization parameters that are directly related to the functionality of hyaluronan. This guide can be used as an aid in the selection and characterization of the appropriate hyaluronan for a particular application. This guide is intended to give guidance in the methods and types of testing necessary to properly characterize, assess, and ensure consistency in the performance of a particular hyaluronan. It may have use in the regulation of these devices by appropriate authorities.

4.2 The hyaluronan covered by this guide may be gelled, cross-linked, extruded, or otherwise formulated into biomedical devices for use in tissue engineered medical products or drug delivery devices for implantation as determined to be appropriate, based on supporting biocompatibility and physical test data. Recommendations in this guide should not be interpreted as a guarantee of clinical success in any tissue engineered medical product or drug delivery application.

4.3 To ensure that the material supplied satisfies requirements for use in TEMP, several general areas of characterization should be considered. These are: identity of hyaluronan,

physical and chemical characterization and testing, impurities profile, and performance-related tests.

5. Chemical and Physical Test Methods

5.1 *Identity of Hyaluronan*—The identity of hyaluronan can be established by several methods including, but not limited to the following:

5.1.1 *Sodium Hyaluronate Monograph EP 1472.*

5.1.2 *Fourier Transform Infrared Spectroscopy (FT-IR)*—Almost all organic chemical compounds absorb infrared radiation at frequencies characteristic for the functional groups in the compound. A FT-IR spectrum will show absorption bands relating to bond stretching and bending and can therefore serve as a unique fingerprint of a specific compound. Direct FT-IR analysis of hyaluronan powder is perhaps the easiest technique to perform. One method utilizes a horizontal attenuated total reflectance (HATR) accessory with a zinc-selenium (ZnSe) crystal (or equivalent) having a sample trough and a pressure plate. Record background and sample spectra between 4000 and 600 cm^{-1} at an appropriate resolution. Label the peaks. Typical frequencies (cm^{-1}) for hyaluronan (sodium salt) are 3275-3390 (b), 1615 (s), 1405 (m), 1377 (m), 1150, 1077, 1045 (s), 946 (m), 893 (w). The peak designators are: sh: sharp; s: strong; m: medium; w: weak; b: broad. A typical FT-IR HATR spectrum is shown in Fig. 1. A reference spectrum can be obtained from the European Pharmacopoeia.¹⁰

5.2 *Physical and Chemical Characterization of Hyaluronan:*

5.2.1 The composition and sequential structure of hyaluronan can be determined by the following method: High-resolution¹H- and ¹³C-nuclear magnetic resonance spectroscopy (NMR). Hyaluronan should be dissolved in D₂O. If the resulting solution is viscous, viscosity may be reduced by chemical or enzymatic depolymerization. A typical¹H-NMR spectrum of hyaluronan is shown below. Hyaluronan is characterized by calculating parameters such as glucuronic acid: N-acetylglucosamine ratio. Some literature references to the determination of composition and structure of hyaluronan are given in the References section (1-4).¹¹

5.2.2 Molecular mass (molecular weight) of hyaluronan will define certain performance characteristics such as viscosity or gel strength, or both. As such and depending on the sensitivity of a particular end use to these variations, determination of molecular mass directly or indirectly may be necessary. Commercial hyaluronan is polydisperse with respect to molecular weight (M_w). M_w may be expressed as the number average (M_N) or the weight average (M_W). Molecular weights may be determined by methods such as, but not limited to the following:

5.2.2.1 *Molecular Weight Determination Based on Intrinsic Viscosity*—The intrinsic viscosity describes a polymer's ability to form viscous solutions in water and is directly proportional to the average molecular weight of the polymer. The intrinsic

¹⁰ EDQM, European Pharmacopoeia, Council of Europe, B.P. 907, F-67029 Strasbourg France; www.pheur.org

¹¹ The boldface numbers in parentheses refer to the list of references at the end of this standard.




FIG. 1 FT-IR Spectrum of Hyaluronan, Sodium Salt Using Horizontal Attenuated Total Reflectance (HATR)




FIG. 2 ^1H NMR Spectrum of Hyaluronan from Rooster Comb ($M_w \sim 700\,000$)

viscosity is a characteristic of the polymer under specified solvent and temperature conditions; it is independent of concentration. The intrinsic viscosity (η) is directly related to the molecular weight of a polymer through the Mark-Houwink-Sakurada (MHS) equation: $[\eta] = KM^a$. For hyaluronan, K is 0.00057 and the exponent (a) is 0.75 at the following condi-

tions: 0.15 M NaCl in phosphate buffer, pH 7.5, 20°C (5). By measuring the intrinsic viscosity, the viscosity average molecular weight can be determined if K and a are accurately known for the sample: $\log [\eta] = \log K + a (\log M)$, where M is the molecular weight. The intrinsic viscosity is determined by measuring the relative viscosity in an Ubbelohde capillary

viscometer. The measurements should be performed in a solvent containing 0.15 M NaCl at a constant temperature of 20°C, and at a sufficiently low hyaluronan concentration. Automatic operation and data acquisition are preferred.

5.2.2.2 Molecular Weight Determination Based on Differential Pressure—Alternatively, a Viscotek Relative Viscometer can be used, which is based on Poiseuille’s law of capillary flow: the pressure drop of a fluid flowing through a capillary is directly proportional to the viscosity.

$$\Delta P = \eta QR$$

where:

ΔP = the pressure drop across the capillary measured by the differential pressure transducer (DPT),

η = the viscosity,

Q = the flow rate, and

R = the resistance of the capillary.

Two capillaries are connected in series with the sample injection valve located between capillary one (1) and capillary two (2). The sample is injected in capillary two (2) and the pressure change is detected by the DPT. The relative viscosity is determined by the ratio of the pressures divided by the instrument constant K .

$$\eta_r = P_2/P_1K$$

The instrument constant K is the ratio of the resistances of capillary one (1) and two (2) at the base line where both capillaries contain pure solvent. Specific viscosity, inherent viscosity, reduced viscosity, and intrinsic viscosity values can be calculated from relative viscosity as follows:

$$\eta_{sp} = \eta_r - 1$$

where:

η_{sp} = specific viscosity.

$$\eta_{red} = \eta_{sp}/C$$

where:

η_{red} = reduced viscosity and C is the concentration.

$$\eta_{int} = \lim (\eta_{sp}/C) \text{ as } C \rightarrow 0$$

where:

η_{int} = the intrinsic viscosity.

From the intrinsic viscosity values, molecular weight can be calculated using the Mark-Houwink-Sakurada equation.

5.2.2.3 Molecular Weight and Polydispersity Determination by Size Exclusion Chromatography with Multiple Angle Laser Light Scattering Detection (SEC-MALLS)—The method of choice is to use refractive index coupled to multiple angle laser light scattering detection (MALLS). For separation of the hyaluronan into different molecular weight fractions, a hydrophilic column with the appropriate pore size is required. Such columns include, but are not limited to those mentioned in the techniques below and in Refs (6, 7). The precision of these techniques must be determined as results can vary by 5 to 20 %. Typical methods using these techniques include, but are not limited to:

(1) Using 0.2 M NaCl as the mobile phase with separation using TSK 3000 and TSK 6000 columns.

(2) Using 150 mM NaCl, 50 mM phosphate buffer as the mobile phase with separation using a Biogel column.

5.2.2.4 Polydispersity—Depending on the end use and the sensitivity of the application to the molecular mass, the presence of a wide range of hyaluronan fractions may be an issue. In such cases, calculation of the polydispersity will be important. Typically this is between 1.2 and 3.0 for commercial hyaluronan.

5.2.3 Depending on the final use and the required performance control, other characterization assays can include, but are not limited to the following:

5.2.3.1 Viscosity in Aqueous Solution—Viscosity is defined as a liquid’s resistance to flow. The molecular mass of hyaluronan will determine the extent to which it will thicken an aqueous solution. Therefore, a simple viscosity test may yield information on the relative differences in molecular mass among hyaluronan samples. To allow comparison between laboratories, the viscometer used must be calibrated with traceable standards (see Test Methods D 2196). The viscosity measured will depend on several parameters related to how the testing is conducted. Both rotational viscometers and “cone on plate” rheometers may be used. Important parameters to control include, but are not limited to:

(1) **Temperature**—The temperature at which the measurement is performed is critical. An increase in temperature will, in almost every case, result in a decrease in the viscosity. Consistent and controlled temperature (that is, with a standard temperature bath) is critical to achieving reproducible results. Typically, the temperature used to measure viscosity can be 20°C, 25°C, or 37°C, or combination thereof.

(2) **Hyaluronan Concentration**—The moisture content of the hyaluronan must be known in order to prepare correct concentrations of hyaluronan (see 5.2.3.2).

(3) **Ionic Strength**—The viscosity of a hyaluronan solution is sensitive to the ionic environment in which the measurement is made. The most important aspect is to keep the ionic strength consistent. Typically viscosity measurements should be made in a standardized ionic environment of known ionic strength.

(4) **Molecular Mass**—Viscosity measurements are sensitive to the molecular mass of hyaluronan. The following is one suggestion concerning the measurement of hyaluronan viscosity, but any appropriate method would apply. To measure the apparent viscosity of hyaluronan, prepare a solution in deionized water with a concentration (w/w , corrected for dry matter content) appropriate for the end use. The viscosity is measured using a rotational viscometer (for example, Brookfield type) at $20 \pm 0.2^\circ\text{C}$ (or other controlled temperature) using the appropriate spindle, spindle rotation speed and a temperature-controlled water bath.

(5) **Shear Rate**—Hyaluronan is sensitive to shear and the viscosity may vary as a function of the shear rate.

5.2.3.2 Dry Matter Content—Hyaluronan from various suppliers may contain different moisture contents. The dry matter content determination is based upon the removal of water and other volatile substances (such as alcohol) from the sample. Normally with hyaluronan, gravimetric techniques are used. They are adapted directly from <731> USP 24/NF19, Loss on Drying, and utilize a calibrated drying oven at 105°C, or EP 2.2.32 by drying at 100 to 110°C over diphosphorus pentoxide for 6 h.

NOTE 1—Dried hyaluronan can reabsorb up to 1 % moisture within 5 min.

5.2.3.3 *pH*—Hyaluronan is generally less stable at acidic pH's. The pH of a 0.5 % solution of hyaluronan should be approximately neutral.

5.2.3.4 *Rheology*—In such instances where testing for viscosity alone may not be sufficient, testing of hyaluronan for viscoelastic properties as measured by dynamic elastic storage modulus and dynamic viscous modulus may be necessary.

5.3 *Impurities Profile*—The term impurity relates to the presence of extraneous substances and materials in the hyaluronan powder. Various processing aids, such as, but not limited to, precipitating agents such as ethanol or other alcohols, may also be used in the manufacture of hyaluronan and could constitute an impurity. Other impurities related to the source of hyaluronate (that is, animal versus non-animal derived hyaluronan) may also be present. Chondroitin sulfates, and in general sulfated glucosamine glycans, are to be considered impurities of hyaluronan when the hyaluronan source is rooster comb or other sources other than bacterial fermentation. If there is a concern for the presence of processing aids or other contaminants associated with hyaluronan, they should be addressed with the supplier. The major impurities of concern include, but are not limited to the following:

5.3.1 *Endotoxin Content*—Endotoxin contamination is difficult to prevent because it is ubiquitous in nature, stable, and small enough to pass through sterilizing filters. There are several tests to determine the presence of endotoxin in the hyaluronan powder. These are the gel clot, endpoint assay, and the kinetic assay. The gel clot test is the simplest and easiest of the Limulus amoebocyte lysate (LAL) test methods, although much less sensitive than the kinetic assay. A firm gel that maintains its integrity upon inverting the tube is scored as a positive test. Anything other than a firm gel is scored as a negative test. The endpoint assay is based on the linear relationship between the endotoxin concentration and the formation of color (chromogenic assay) over a relatively short range of standard dilutions. A standard curve is then constructed by plotting the optical densities of a series of endotoxin standards as a function of the endotoxin concentration. The most sensitive means of determining the endotoxin content is with a quantitative, kinetic assay. This test utilizes a Limulus Amoebocyte Lysate (LAL) and a synthetic color producing substrate to detect endotoxin chromogenically. The kinetic assay measures the amount of time required to reach a predetermined optical density (kinetic turbidimetric) or color intensity (kinetic chromogenic), sometimes called the onset optical density or reaction optical density. FDA currently defines linearity as a correlation coefficient of ≥ 0.980 (Food and Drug Administration Guideline). Positive product controls (PPC) must be added to test inhibition in the sample. Recovery of the known added amount of endotoxin standard must be obtained for a valid assay. The endotoxin level in hyaluronan will ultimately be critical to its use in biomedical applications where there are regulatory limits to the amount of endotoxin that can be implanted into humans. Relevant FDA guidance for allowable levels and information regarding validation of endotoxin assays should be consulted if human trials are contemplated

(FDA Interim Guidance for Human and Veterinary Drug Products and Biologicals). If intended for use in the manufacture of parenteral dosage forms without a further appropriate procedure for the removal of bacterial endotoxins, then the endotoxin content limit shall be less than 0.5 EU/mg (that is, 500 EU/g). If intended for use in the manufacture of intra-ocular preparations or intra-articular preparations without a further appropriate procedure for the removal of bacterial endotoxins, then the endotoxin content limit shall be less than 0.05 EU/mg (that is, 50 EU/g) (EP 1472).

5.3.2 *Nucleic Acids*—Hyaluronan may contain nucleic acids or nucleotides. Occurrence of these impurities is detected by evaluating the absorbance at 260 nm spectrophotometrically where purine and pyrimidine bases absorb light but hyaluronan does not (EP 1472).

5.3.3 *Protein Content*—Protein content in hyaluronan should be assayed using an appropriate method having sufficient sensitivity to detect low levels of contamination. It is important to confirm that the method chosen is insensitive to materials present in the sample and to validate it against a reference method on a one-time basis. It is the responsibility of the end user to evaluate the hyaluronan product for the presence of specific proteins that could cause undesirable immunological or tissue reactions.

5.3.4 *Sulfated Glycosaminoglycans*—Hyaluronan may contain sulfated glycosaminoglycans such as chondroitin sulfate or other mucopolysaccharide sulfates. The presence of sulfates can be determined as a limit test following mineralization of hyaluronan (EP 1472) or by quantifying sulfur content using an appropriate method such as, but not limited to, Inductively Coupled Plasma spectroscopy (ICP).

5.3.5 *Iron*—Iron content may be determined by a number of techniques, however the analytical method chosen must be able to detect iron to a level of 80 ppm in the final product, a level suggested in EP 1472 as the maximum iron content. Iron may also be one of the metals analyzed by ICP (see 5.3.6.2).

5.3.6 *Heavy Metal Content:*

5.3.6.1 *USP Method*—This test is to demonstrate that the content of heavy metal impurities does not exceed a predetermined limit in terms of ppm in the test substance. Under the specified test conditions, the limit is evaluated by a concomitant visual comparison of metals that are colored by sulfide ion with a control prepared from a Standard Lead Solution. Substances that typically respond to this test are lead, mercury, bismuth, arsenic, antimony, tin, cadmium, silver, copper, and molybdenum. This test method is based on USP <231> Heavy Metals.

5.3.6.2 *ICP and ICP-MS*—Inductively coupled plasma (ICP) with or without mass spectrometry (MS) allows the simultaneous analysis of multiple elements. Depolymerization of viscous hyaluronan solutions may be required for appropriate sample introduction into the plasma.

5.3.7 *Microbiological Safety*—The presence of bacteria, yeast and mold are also impurities that can arise in a hyaluronan sample. The presence of bacteria may also contribute to the presence of endotoxins. The following Microbiological Tests in USP 24 are of particular relevance: <61>, <71>, <1211>, and <85>. The user should also consider other relevant standards,

such as, but not limited to, Association for the Advancement of Medical Instrumentation (AAMI) standards and international standards, of which the following are examples: ANSI/AAMI/ISO 11737-1: 1995, ANSI/AAMI/ISO 11737-2: 1998, and ISO 13408-1: 1998.

6. Product Development Considerations

6.1 *Source of Hyaluronan*—Hyaluronan may be produced from several sources. The source of hyaluronan may impact on the final regulatory approval of the hyaluronan-containing formulation or device. Hyaluronan may be processed from:

6.1.1 *Animal-derived:*

6.1.1.1 Avian sources such as rooster and hen comb.

6.1.1.2 Bovine sources such as synovial fluid or vitreous humor.

6.1.1.3 Other sources such as human umbilical cord.

6.1.2 *Non-animal Derived:*

6.1.2.1 Fermentation with *Streptococci* sp.

6.1.2.2 Fermentation with *Bacillus* sp.

6.1.2.3 Other sources.

6.2 The designation “non-animal derived” refers to the total absence of animal-derived products in the production process. Beef extracts and milk protein such as casein used in fermentation medium, as well as animal-derived processing aids such as enzymes, may affect the labeling of hyaluronan. Suppliers of hyaluronan should be requested to document that the fermentation process for “non-animal derived” hyaluronan does not employ any animal-derived fermentation products.

6.3 *Stability of Hyaluronan*—For hyaluronan, the most relevant stability-indicating parameters are those related to the functionality of the polymer. Dependent upon what function the hyaluronan will have in the final formulation, parameters such as viscosity (apparent and intrinsic) and molecular weight should be evaluated during a stability study. Storage conditions are of importance, especially for hyaluronan solutions. International Conference on Harmonization (ICH) guidance documents should be consulted for information on stability testing of pharmaceuticals (that is, ICH Q1A).

6.4 *Sterility:*

6.4.1 Sterilization is intended for the final application or formulation. If sterilization of the hyaluronan is required, then there are several alternative methods available. However, the listing of alternative sterilization methods does not imply that commercial suppliers of hyaluronan need provide a sterile product. Hyaluronan powder can be sterilized by gamma irradiation (with subsequent degradation of the hyaluronan chain resulting in a reduction in molecular weight) or by ethylene oxide or vaporized peroxide (gas plasma). Solutions of hyaluronan may be (1) aseptically formulated from sterile hyaluronan powder, (2) filter sterilized if the viscosity of the hyaluronan solution permits; (3) gamma-irradiated with a resulting loss in viscosity (molecular weight); and (4) autoclaved (which also reduced the viscosity of the solution). Solution sterilization using gamma irradiation or heat autoclaving may result in the decomposition of the product (see 3.1.6). Selection of the method of sterilization will depend upon the

viscosity or molecular weight needs of the final application. Use of ethylene oxide or peroxide will also require testing for residuals. The reader should refer to the relevant standards regarding the sterilization of healthcare products by radiation, steam and ethylene oxide gas, such as AAMI TIR No. 7:1999, ISO 10993-7:1995, ISO 14160:1998, and AAMI ST67/CDV-2: 1999.

6.4.2 The method of sterilization may affect the physical, chemical, and functional properties of hyaluronan. Hyaluronan should be re-analyzed after sterilization.

6.4.3 If intended for use in the manufacture of sterile forms without a further appropriate sterilization procedure, hyaluronan must conform to tests for sterility such as USP <71> or EP 2.6.1.

7. Safety and Toxicology Aspects of Hyaluronan

7.1 The safety of hyaluronan in biomedical and pharmaceutical applications and in Tissue Engineered Medical Products (TEMPs) should be established according to current guidelines such as ISO 10993 or Practice F 748. Suppliers of hyaluronan may have such documentation on file. Preclinical safety studies specific to the clinical application under consideration must also be done in accordance with 21 CFR 312.

7.2 *Biocompatibility:*

7.2.1 Biomaterials are materials of natural or manmade origin that are used to direct, supplement, or replace the functions of living tissues. When the biological response of these materials is minimal, they have come to be termed biocompatible (12).

7.2.2 Many materials have been shown to produce a well-characterized level of biological response following long term clinical use in laboratory animals. When new applications of a material, or modifications to the material or physical forms of the material are being considered, then the recommendations and test methods of the following standards should be considered: Practices F 748, F 619, F 749, F 756, F 763, F 813, and F 981, F 1439 as well as Test Method F 895 and ISO 10993-1, ISO 10993-9, Part 9, ISO/DIS 10993-17-Part 17, ISO EN 12442-1-Part 1, ISO EN 12442-3-Part 3. Additional guidance can be obtained in ICH S2B.

7.2.3 The presence of low molecular weight fragments of hyaluronan in a product may affect its biocompatibility. Tests to detect these fragments may be necessary, as such fragments may have the potential for initiating an inflammatory response (8, 9).

7.3 Hyaluronan for use in biomedical and pharmaceutical applications and in Tissue Engineered Medical Products (TEMPs) should ideally be documented in a device or drug master file to which end users may obtain a letter of cross reference from suppliers of hyaluronan. Such a master file should be submitted to the US FDA and to other regulatory authorities, both national and international.

8. Keywords

8.1 biomaterials; biopolymer; hyaluronan; polysaccharide; TEMPs

APPENDIXES

(Nonmandatory Information)

X1. RATIONALE

X1.1 The use of naturally occurring biopolymers for biomedical and pharmaceutical applications and in Tissue Engineered Medical Products (TEMPs) is increasing. This guide is designed to give guidance in the characterization and testing parameters for hyaluronan used in such applications. The term “hyaluronan” is used to describe both the acid form and its salts. Knowledge of the physical and chemical proper-

ties of the hyaluronan, such as molecular weight, for instance, will assist end users in choosing the correct hyaluronan for their particular application. Knowledge of these parameters will also ensure that users can request and obtain similar material from suppliers on reordering. Finally, characterization of the hyaluronan will allow the functionality of the hyaluronan to fit the application or end product.

X2. BACKGROUND

X2.1 Hyaluronan is an unbranched polysaccharide consisting of alternating glucuronic acid and N-acetylglucosamine units. The length of the polymer chain is rather long in native form, but may decrease during the manufacturing process. Hyaluronan is the simplest glycosaminoglycan and does not have sulfate groups. Hyaluronan is not found bound to protein, therefore, it is not considered a protein-bound proteoglycan. It is found as a constituent of all body fluids and tissues, in higher concentrations in the vitreous humor the eye and in synovial fluid in the joints. Solutions of hyaluronan can be very viscous and are lubricious. The molecular weight of commercial hyaluronan may vary between 100 000 and 3 000 000 g/mol, similar to a degree of polymerization (DP) of approximately 2500 and above. Information on hyaluronan, its biology and biochemistry, may be found at <http://www.glycoforum.gr.jp/science/hyaluronan/hyaluronanE.html> (10) and in reference (11). The Glycoforum web site is organized by Seikagaku. Glycoforum, and is intended as a public service to present short articles on current, exciting research activities in glycobiology.

plexed with proteoglycans. Hyaluronan has also been extracted from human umbilical cord.

X2.2.2 *Bacterial Fermentation*—Lancefield’s group A and C *Streptococci sp.* naturally produce a mucoid capsule of hyaluronan. Another micro-organism used in fermentation of hyaluronan is *Bacillus subtilis*. There are other microorganisms that can synthesize hyaluronan.

X2.3 *Metabolism:*

X2.3.1 The half-life of hyaluronan in blood is very short, only a few minutes.

X2.3.2 Hyaluronan is synthesized and catabolized by cells such as chondrocytes in cartilage. The half-life of hyaluronan in cartilage is about 2 to 3 weeks. Keratinocytes in the epidermis also synthesize and catabolize hyaluronan. In the skin, the half-life of hyaluronan is about 1 day.

X2.3.3 Tissues in joints, such as cells lining the knee joint capsule, synthesize hyaluronan and release it into the synovial fluid. Synovial fluid drains through the lymphatic system




FIG. X2.1 Repeating Unit of Sodium Glucuronate-β-1,3-N-acetylglucosamine Linked by β-1,4 Bonds

X2.2 *Raw Materials for Hyaluronan Production*—Hyaluronan is commercially produced either from tissue extracts or from cultured microorganisms.

X2.2.1 *Tissue Sources*—These include avian sources (rooster and hen comb), bovine vitreous humor, and bovine synovial fluid. Hyaluronan from these sources may be com-

before entry into the blood.

X2.3.4 Reticulo-endothelial cells lining the lymphatic system actively remove almost 90 % of the hyaluronan before the remainder reaches the vascular system.

X2.3.5 It has been estimated that almost one third of the total hyaluronan in the human body is metabolically removed and replaced every 24 h.

X2.4 *Functional Properties and Applications of Hyaluronan:*

X2.4.1 The functional properties of hyaluronan of primary importance for most biomedical applications are related to hyaluronan molecular weight. The viscosity properties of hyaluronan will be directly related to molecular weight. Solubility, swellability, and viscoelastic properties are other characteristics exploited in biomedical and pharmaceutical applications.

X2.4.2 The carboxyl groups of hyaluronan are completely ionized at pH 7.

X2.4.3 Hyaluronan in solution forms hydrogen bonds between water molecules and adjacent carboxyl and *N*-acetyl groups. Hydrogen bond formation results in extensive water-binding capacity of the polymer.

X2.4.4 *Ophthalmology*—Hyaluronan is used for ophthalmic viscosurgery where it provides protection and maintains the shape of the anterior chamber during surgery.

X2.4.5 *Osteoarthritis*—Hyaluronan can be used to supplement the synovial fluid in osteoarthritic joints thereby providing pain relief.

X2.4.6 *Anti-adhesion*—Hyaluronan is used to reduce the incidence and severity of post-surgical adhesions.

X2.4.7 *Tissue Engineering*—Hyaluronan is used as a matrix material in bone repair/bond graft products. Cross-linked hyaluronan is being used to form scaffolds. However, cross-linking is a chemical reaction that modifies hyaluronan by introducing foreign molecules (spacers). The resulting cross-linked hyaluronan may require further testing by methods not outlined in this Guide.

X2.4.8 *Cosmetic and Dermal Applications*—Hyaluronan-based dermal implants are used to provide lip augmentation or correct contour deficiencies such as wrinkles or scarring. The water-binding capacity of hyaluronan is also used in many emollient formulations.

REFERENCES

- (1) Bociek, S. M., Darke, A. H., Welti, D., and Rees, D.A., "The ^{13}C -NMR Spectra of Hyaluronate and Chondroitin Sulphates," *Eur. J. Biochem.*, 109, 1980, pp. 447-456.
- (2) Scott, J. E., Heatley, F., Moorcroft, D., and Olavesen, A. H., "Secondary Structures of Hyaluronate and Chondroitin Sulphates," *Biochem. J.*, 199, 1981, pp. 829-832.
- (3) Scott, J. E., Heatley, F., and Hull, W. E., "Secondary Structure of Hyaluronate in Solution," *Biochem. J.*, 220, 1984, pp. 197-205.
- (4) Toffanin, R., Kvam, B. J., Flaibani, A., Atzori, M., Biviano, F., and Paoletti, S., "NMR Studies of Oligosaccharides Derived from Hyaluronate: Complete Assignment of ^1H and ^{13}C NMR Spectra of Aqueous Di- and Tetra-saccharides, and Comparison of Chemical Shifts for Oligosaccharides of Increasing Degree of Polymerisation," *Carbohydrate Res.*, 245, 1993, pp. 113-128.
- (5) Terbojevich, M., Cosani, A., Palumbo, M., and Pregnotato, F., "Structural Properties of Hyaluronic Acid in Moderately Concentrated Solutions," *Carbohydrate Res.*, 149, 1986, pp. 363-377.
- (6) Beaty, N. B., Tew, W. P., and Mello, R. J., "Relative Molecular Weight and Concentration Determination of Sodium Hyaluronate Solutions by Gel-Exclusion High-Performance Liquid Chromatography," *Anal. Biochem.*, 147, 1985, pp. 387-395.
- (7) Ueno, Y., Tanaka, Y., Horie, K., and Tokuyasu, K., "Low-angle Laser Light Scattering Measurements on Highly Purified Sodium Hyaluronate from Rooster Comb," *Chem. Pharm. Bull.*, 36, 1988, pp. 4971-4975.
- (8) McKee, C. M., Penno, M. B., Cowman, M., Burdick, M. D., Strieter, R. M., Bao C., and Noble, P. W., "Hyaluronan (HA) Fragments Induce Chemokines Gene Expression in Alveolar Macrophages. The Role of HA Size and CD44," *J. Clin. Invest.*, 98, 1996, pp. 2403-2413.
- (9) Haslinger, B., Mandl-Weber, S., Sellmayer, A., and Sitter, T., "Hyaluronan Fragments Induce the Synthesis of MCP-1 and IL-8 in Cultured Human Peritoneal Mesothelial Cells," *Cell Tissue Res.*, 305, 2001, pp. 79-86.
- (10) <http://www.glycoforum.gr.jp/science/hyaluronan/hyaluronanE.html>
- (11) *The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives*. T. C. Laurent, ed., Portland Press, Colchester, UK, 1998.
- (12) Black, J., *Biological Performance of Materials*, Marcel Dekker, Inc., New York, 1999, p.3.

ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.

This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.

This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or service@astm.org (e-mail); or through the ASTM website (www.astm.org).